AFC-HD AMS Life Science Co., Ltd. (TSE:2927), a Japanese company specializing in the contract manufacturing and sales of health food products, generic pharmaceuticals, and traditional Chinese medicine, reported a modest revenue increase for the full fiscal year ending August 2026, but faced declining profitability across key metrics. The company also announced a revision to its earnings forecast, signaling a cautious outlook for the coming year.
Key Numbers (JPY bn/M)
| Metric | FY2026 (Actual) | YoY Change |
|---|---|---|
| Revenue | 16.8 | +1.4% |
| Operating Profit | 1.25 | -3.4% |
| Ordinary Income | 1.19 | -10.4% |
| Net Profit | 801M | -9.1% |
| Operating Margin | 7.4% | — |
| Equity Ratio | 31.9% | — |
Business Overview
AFC-HD AMS Life Science Co., Ltd. operates in the health food, cosmetics, and pharmaceutical manufacturing sectors, and has expanded into real estate, leasing, and tourism through the acquisition of Saika Department Store and the establishment of AFC Tourism Co., Ltd. The company is positioned to benefit from the growing demand for generic drugs and traditional medicine in Japan.
Analysis
Despite a 1.4% year-over-year (YoY) increase in revenue, the company saw declines in operating profit, ordinary income, and net profit. Specifically, these three metrics fell by 3.4%, 10.4%, and 9.1%, respectively. The operating margin of 7.4% remained above the industry average of 6.0%, reflecting the company’s ability to maintain profitability through high-value manufacturing and stable demand for its pharmaceutical products.
However, the decline in profitability is attributed to rising costs, pricing pressures, and increasing raw material prices—challenges that are common across the industry. The company has also been diversifying its operations, with a focus on expanding its tourism and real estate businesses, including the integration of Rabbit Express Co., Ltd. into its group structure.
Next Year Guidance
The company has provided the following guidance for the next fiscal year:
| Metric | FY2027 (Forecast) | YoY Change (vs. FY2026 Actual) |
|---|---|---|
| Revenue | 34.137bn | +4.5% |
| Operating Profit | 2.545bn | +5.6% |
| Ordinary Income | 2.445bn | +0.1% |
| Net Profit |
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.